## ABVX: ABIVAX Société Anonyme - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-11.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. How Abivax (ABVX) Turned Heads With Whopping 1700% Surge in 2025**
- Source: Insider Monkey | 20260102T090911 | Bullish | Relevance: 100%
- ABIVAX Societe Anonyme (NASDAQ:ABVX) surged over 1,700% in 2025, becoming the year's top performer, driven by positive analyst outlooks, strong clinical trial results, and inclusion in the Nasdaq Biotechnology Index. The company's obefazimod showed significant improvement in Phase 3 trials for ulcerative colitis, earning "buy" recommendations and high price targets from several investment firms.

**2. Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end**
- Source: ts2.tech | 20260101T130942 | Somewhat-Bearish | Relevance: 100%
- Abivax's U.S.-listed shares saw a drop today as traders trimmed their bets on an Eli Lilly takeover by year-end, following a month of significant stock swings driven by takeover rumors and index-related flows. Investors are closely monitoring for new comments on strategic interest and upcoming obefazimod data updates. The pullback could be attributed to year-end positioning intersecting with headline risk after a prior surge fueled by deal talk.

**3. Is ABIVAX Societe Anonyme (ABVX) One of the Hottest Large-Cap Stocks of 2025?**
- Source: Finviz | 20251231T112500 | Bullish | Relevance: 100%
- ABIVAX Société Anonyme (NASDAQ: ABVX) is highlighted as one of the hottest large-cap stocks of 2025 due to recent price target increases from Piper Sandler and Citizens. The company's Q3 2025 results showed a significant increase in cash reserves following a large public offering, extending its cash runway into Q4 2027. Despite a widening net loss attributed to increased R&D and personnel expenses for advancing its clinical trials, analysts remain optimistic about its potential, particularly for its ulcerative colitis drug.

**4. Abivax Shares Tumble: What Investors Need to Know**
- Source: StocksToTrade | 20260101T000942 | Bearish | Relevance: 100%
- Abivax SA shares have steeply declined by -4.84% following a wider-than-expected third-quarter loss and amidst broader market caution. The biopharma company reported a net loss despite strong operating cash flow, with concerns arising from increased total expenses and significant long-term debt. Investors are weighing these financial challenges against the company's strategic growth ambitions and competitive market landscape.

**5. Voya Investment Management LLC Invests $978,000 in Abivax SA Sponsored ADR $ABVX**
- Source: MarketBeat | 20251231T133213 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC has acquired a new stake of 11,515 shares, valued at approximately $978,000, in Abivax SA Sponsored ADR ($ABVX) during the third quarter. Other institutional investors also adjusted their holdings in the clinical-stage biopharmaceutical company, which has a market cap of $10.78 billion. Despite reporting a quarterly loss, analysts generally maintain a "Moderate Buy" rating with an average target price of $128.73 for Abivax.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Citizens | $131 | $114 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Citizens | main | Market Outperform |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (7.9x), low leverage (D/E 0.28). Revenue growth strong at 605% YoY. Analyst sentiment positive (1 raises, avg +15%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.6B |
| Beta | -0.11 |
| 52W Range | $4.77 - $148.83 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 11.6% to 0.5% (-11.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 (-2.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.53), confirming momentum. RSI neutral at 58. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.48% (CS: 45) | Neutral |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | 0.53 | Bullish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.160x | Above |
| vs SMA200 | 2.325x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $133.77
- **Stop Loss:** $117.83 (11.9% risk)
- **Target:** $149.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $12,039.30
- **Portfolio %:** 12.04%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*